tegafur has been researched along with Uterine Cervical Neoplasms in 48 studies
Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.
| Excerpt | Relevance | Reference |
|---|---|---|
| " 5-Fluorouracil (5-FU) was effective against only one bladder cancer xenograft among 6 cancer xenografts tested." | 3.68 | [Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice]. ( Adachi, S; Akaza, H; Ishitsuka, H; Kanazawa, K; Miwa, M; Nitta, K; Sekiguchi, F; Tokita, H, 1991) |
| " The other 36 received CRC at the same cisplatin and radiotherapy dosage as for CRSC." | 2.82 | Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial. ( Han, S; Li, Z; Lin, N; Mao, W, 2016) |
| "Irinotecan was administered intravenously over the course of 90 minutes on day 1, and S-1 was given orally in 2 divided doses from days 1 to 14 of a 21-day cycle." | 2.82 | Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy. ( Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E, 2016) |
| "This phase II study of S-1 in cervical cancer suggests a promising response rate and a contribution toward prolonging survival, with modest toxic effects." | 2.76 | Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. ( Hatae, M; Hirai, Y; Kamiura, S; Katsumata, N; Kokawa, K; Nishimura, R; Ochiai, K; Sugiyama, T, 2011) |
| "The stage IIB-IIIB cervical cancer patients were randomized to have Tegafur-Uracil 225 mg/m(2)/day orally, 5 days a week and carboplatin 100 mg/m(2) IV over 30-60 min, weekly on day 1 concurrent with standard radiotherapy (Group A) or carboplatin alone concurrent with standard radiotherapy (Group B)." | 2.73 | A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: preliminary results. ( Kamnerdsupaphon, P; Khorprasert, C; Lertsanguansinchai, P; Lorvidhaya, V; Sangruchi, S; Sookpreedee, L; Suntornpong, N; Udompunturak, S; Veerasarn, V, 2007) |
| " The Kaplan-Meier overall and cancer specific survival analysis estimates that the chronic administration of antimetabolites did not improve the cumulative 5-year survival in the SCC group." | 2.68 | [Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer]. ( Hirota, Y; Hongo, J; Iijima, Y; Inagaki, M; Koyama, M; Ozaki, M; Wada, K, 1995) |
| "Total 21 cases of cervical cancer were alloted randomly into 5'-DFUR group (daily dose 800 mg for 3 days) consisting of 11 patients and UFT group (daily dose 600 mg for 3 days) consisting of 10 patients, the unchanged substances (5'-DFUR in the 5'-DFUR group and tegafur concentrations in the UFT group) and 5-FU concentrations in serum and tissues were measured 6 hours after administration of the drugs." | 2.68 | [5-FU concentrations in the blood and tumor tissue after 5'-DFUR or UFT administration in the patients with uterine cervical cancer]. ( Aida, I; Kasuga, Y; Ohwada, M; Sato, I; Suzuki, M; Tamura, T, 1995) |
| "Complete cases among them consisted of ovarian cancer 53 cases, uterine cervical cancer 86 cases and endometrial cancer 27 cases for a total of 166 cases." | 2.67 | [Maintenance chemotherapy using UFT and FT for gynecological malignant tumors. The Gunma Prefectural Society for Study of Chemotherapy for Gynecological Cancer]. ( Ibuki, Y; Igarashi, M; Ito, T; Kimura, H; Kosuge, T; Nagayama, M; Nogami, Y; Ohwada, N; Tsukagoshi, T; Yazaki, K, 1992) |
| "A large proportion of recurrent cervical cancer (RCC) patients present with poor performance status (PS) after comprehensive treatments, which usually prevents them from opting for clinical trials." | 1.56 | Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series. ( Jiang, SN; Shang, YP; Wang, ZM; Xu, XJ, 2020) |
| " The following pharmacokinetic results were obtained in comparison with single administration." | 1.27 | [Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram]. ( Chin, N; Endoh, S; Fukui, H; Hasegawa, T; Hayashi, Y; Ishii, Y; Kohno, I; Nakagiri, Y; Okazaki, H; Rin, K, 1984) |
| " The drug sensitivity of the cultured cancer cells was investigated with a colony forming assay, and a dose-response curve was obtained for the time-dependent anticancer drug." | 1.27 | [Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment]. ( Maeda, T, 1986) |
| " Daily dosage of FT-207 was either 600 or 800 mg and the drug was administered orally." | 1.26 | [FT-207 maintenance therapy of malignant gynecologic cancer]. ( Jimi, S; Kato, Y; Kawakami, M; Kidera, Y; Matsuyama, T; Morita, T; Nishimura, A; Shigyo, R; Sugimori, H; Tanaka, M; Toyota, Y; Tsukamoto, N; Watanabe, E; Yamashita, H, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (47.92) | 18.7374 |
| 1990's | 9 (18.75) | 18.2507 |
| 2000's | 5 (10.42) | 29.6817 |
| 2010's | 10 (20.83) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, XJ | 1 |
| Wang, ZM | 1 |
| Shang, YP | 1 |
| Jiang, SN | 1 |
| Ma, L | 1 |
| Liu, JM | 1 |
| Zhang, J | 1 |
| Li, H | 1 |
| Aoki, Y | 1 |
| Ochiai, K | 2 |
| Lim, S | 1 |
| Aoki, D | 1 |
| Kamiura, S | 2 |
| Lin, H | 1 |
| Katsumata, N | 3 |
| Cha, SD | 1 |
| Kim, JH | 1 |
| Kim, BG | 1 |
| Hirashima, Y | 1 |
| Fujiwara, K | 2 |
| Kim, YT | 1 |
| Kim, SM | 1 |
| Chung, HH | 1 |
| Chang, TC | 1 |
| Kamura, T | 1 |
| Takizawa, K | 1 |
| Takeuchi, M | 1 |
| Kang, SB | 1 |
| Takatori, E | 1 |
| Shoji, T | 1 |
| Suga, Y | 1 |
| Niinuma, H | 1 |
| Miura, Y | 1 |
| Kaido, Y | 1 |
| Takada, A | 1 |
| Kagabu, M | 1 |
| Takeuchi, S | 1 |
| Sugiyama, T | 2 |
| Yunokawa, M | 3 |
| Yamamoto, H | 1 |
| Kodaira, M | 1 |
| Yonemori, K | 1 |
| Shimizu, C | 1 |
| Ando, M | 1 |
| Tamura, K | 1 |
| Fujiwara, Y | 1 |
| Sakaguchi, I | 1 |
| Motohara, T | 1 |
| Saito, F | 1 |
| Takaishi, K | 1 |
| Fukumatsu, Y | 1 |
| Tohya, T | 1 |
| Shibata, S | 2 |
| Mimori, H | 1 |
| Tashiro, H | 1 |
| Katabuchi, H | 1 |
| Li, Z | 1 |
| Mao, W | 1 |
| Lin, N | 1 |
| Han, S | 1 |
| Tanigawa, T | 1 |
| Matoda, M | 1 |
| Yamamoto, A | 1 |
| Nomura, H | 1 |
| Okamoto, S | 1 |
| Sakamoto, K | 1 |
| Kondo, E | 1 |
| Omatsu, K | 1 |
| Kato, K | 1 |
| Takeshima, N | 1 |
| Mabuchi, S | 1 |
| Yokoi, E | 1 |
| Owa, T | 1 |
| Kozasa, K | 1 |
| Yamashita, M | 1 |
| Kobayashi, E | 1 |
| Tomimatsu, T | 1 |
| Yoki, T | 1 |
| Tsutui, T | 1 |
| Kimura, T | 1 |
| Nagai, N | 3 |
| Komatsu, M | 2 |
| Shiroyama, Y | 1 |
| Hirata, E | 2 |
| Pérez-Regadera, J | 1 |
| Sánchez-Muñoz, A | 1 |
| De-la-Cruz, J | 1 |
| Ballestín, C | 1 |
| Lora, D | 1 |
| García-Martín, R | 1 |
| Alonso-Carrión, L | 1 |
| Mendiola, C | 1 |
| Lanzós, E | 1 |
| Hirai, Y | 1 |
| Kokawa, K | 1 |
| Hatae, M | 2 |
| Nishimura, R | 1 |
| Veerasarn, V | 1 |
| Lorvidhaya, V | 1 |
| Kamnerdsupaphon, P | 1 |
| Suntornpong, N | 1 |
| Sangruchi, S | 1 |
| Lertsanguansinchai, P | 1 |
| Khorprasert, C | 1 |
| Sookpreedee, L | 1 |
| Udompunturak, S | 1 |
| Mukai, K | 1 |
| Jin, HH | 1 |
| Takagi, K | 1 |
| Kougo, H | 1 |
| Aoyagi, Y | 1 |
| Yonehara, T | 1 |
| Minobe, S | 1 |
| Azuma, M | 1 |
| Yamaguchi, T | 1 |
| Nagai, S | 2 |
| Sawada, T | 1 |
| Kawai, Y | 2 |
| Hirano, H | 2 |
| Taniguchi, H | 2 |
| Tamaishi, Y | 1 |
| Nishimura, K | 1 |
| Asakura, T | 1 |
| Ri, T | 1 |
| Uematsu, A | 2 |
| Sugiyama, Y | 2 |
| Okazaki, H | 2 |
| Hasegawa, T | 2 |
| Fujimori, T | 1 |
| Katayama, S | 1 |
| Sakaguchi, K | 1 |
| Hayashi, Y | 2 |
| Nakagiri, Y | 2 |
| Ishii, Y | 2 |
| Fukui, H | 2 |
| Kohno, I | 3 |
| Endoh, S | 1 |
| Chin, N | 1 |
| Rin, K | 1 |
| Noda, T | 1 |
| Kamamoto, Y | 1 |
| Saitoh, S | 1 |
| Nakanishi, A | 1 |
| Ando, Y | 1 |
| Tsuji, Y | 1 |
| Yoh, S | 1 |
| Moriyama, I | 1 |
| Ichijo, M | 1 |
| Terahara, M | 1 |
| Hokanishi, H | 1 |
| Maeda, T | 4 |
| Okamura, S | 3 |
| Ueki, M | 3 |
| Kidera, Y | 1 |
| Sugimori, H | 2 |
| Tanaka, M | 1 |
| Jimi, S | 1 |
| Watanabe, E | 1 |
| Kato, Y | 1 |
| Morita, T | 1 |
| Shigyo, R | 1 |
| Yamashita, H | 1 |
| Nishimura, A | 1 |
| Kawakami, M | 1 |
| Toyota, Y | 1 |
| Tsukamoto, N | 2 |
| Matsuyama, T | 1 |
| Yamada, E | 1 |
| Shimizu, A | 1 |
| Watanabe, S | 1 |
| Okuyama, D | 1 |
| Morioka, M | 1 |
| Yoda, A | 1 |
| Hoshino, K | 1 |
| Noguchi, Y | 1 |
| Takahashi, J | 1 |
| Notake, Y | 1 |
| Mitsuya, T | 1 |
| Wada, K | 1 |
| Koyama, M | 1 |
| Iijima, Y | 1 |
| Inagaki, M | 1 |
| Hirota, Y | 1 |
| Hongo, J | 1 |
| Ozaki, M | 1 |
| Suzuki, M | 3 |
| Aida, I | 1 |
| Ohwada, M | 2 |
| Sato, I | 1 |
| Tamura, T | 1 |
| Kasuga, Y | 1 |
| Kato, T | 1 |
| Yakushiji, M | 1 |
| Yamabe, T | 1 |
| Hidaki, T | 1 |
| Tazaki, T | 1 |
| Baba, M | 1 |
| Shima, T | 1 |
| Tanaka, T | 2 |
| Nakayabu, M | 1 |
| Hasegawa, H | 1 |
| Suzuki, S | 1 |
| Kusano, I | 1 |
| Oshita, T | 1 |
| Shigemasa, K | 1 |
| Ohama, K | 1 |
| Takehara, K | 1 |
| Miyaoka, S | 1 |
| Shiota, M | 1 |
| Shirai, T | 1 |
| Tateyama, I | 1 |
| Ohwada, N | 1 |
| Nagayama, M | 1 |
| Kosuge, T | 1 |
| Tsukagoshi, T | 1 |
| Ibuki, Y | 1 |
| Igarashi, M | 1 |
| Yazaki, K | 1 |
| Ito, T | 1 |
| Nogami, Y | 1 |
| Kimura, H | 1 |
| Miwa, M | 1 |
| Sekiguchi, F | 1 |
| Akaza, H | 1 |
| Tokita, H | 1 |
| Nitta, K | 1 |
| Adachi, S | 1 |
| Kanazawa, K | 1 |
| Ishitsuka, H | 1 |
| Sekiguchi, I | 2 |
| Tamada, T | 2 |
| Rigano, A | 1 |
| Adamo, V | 1 |
| Altavilla, G | 1 |
| d'Aquino, S | 1 |
| Yabushita, H | 1 |
| Sawaguchi, K | 1 |
| Ueno, N | 1 |
| Hieda, S | 1 |
| Noguchi, M | 1 |
| Ishihara, M | 1 |
| Yamashita, K | 1 |
| Mitani, K | 1 |
| Morishita, Y | 1 |
| Inoue, K | 2 |
| Sugawa, T | 2 |
| Yamagata, S | 2 |
| Tanimura, T | 1 |
| Kaneshige, E | 2 |
| Kobashi, Y | 1 |
| Kono, I | 1 |
| Sekiba, K | 2 |
| Kamiya, H | 1 |
| Sato, K | 1 |
| Sakai, K | 1 |
| Sugimoto, O | 1 |
| Shiromizu, K | 1 |
| Matsuzawa, M | 1 |
| Takahashi, M | 1 |
| Ishihara, O | 1 |
| Noda, K | 1 |
| Teshima, K | 1 |
| Ikeda, M | 1 |
| Sawaragi, I | 1 |
| Matsuoka, I | 1 |
| Inoue, S | 1 |
| Okumura, A | 1 |
| Onitsuka, Y | 1 |
| Yoshimura, T | 1 |
| Aiko, A | 1 |
| Ikuta, Y | 1 |
| Fukuma, K | 1 |
| Matsuura, K | 1 |
| Nishiyama, M | 1 |
| Yanase, H | 1 |
15 trials available for tegafur and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
A pilot study of oral S-1 for treating heavily pretreated patients with advanced or recurrent cervical cancer among Chinese population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; China; Disease-Free Survival; Drug Combinations; Feasi | 2018 |
Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 2018 |
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2013 |
High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; | 2015 |
Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Fem | 2016 |
Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; | 2016 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2016 |
Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Human | 2011 |
A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Huma | 2007 |
[Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer].
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluo | 1995 |
[5-FU concentrations in the blood and tumor tissue after 5'-DFUR or UFT administration in the patients with uterine cervical cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; Fluoroura | 1995 |
[A multicenter cooperative study on supplementary chemotherapy of uterocervical cancer. The Kyushu UFT Study Group of Uterocervical Cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1994 |
[Maintenance chemotherapy using UFT and FT for gynecological malignant tumors. The Gunma Prefectural Society for Study of Chemotherapy for Gynecological Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Humans; | 1992 |
[Phase II study of UFT in cancer of the uterine cervix].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1985 |
33 other studies available for tegafur and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged | 2020 |
A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 2014 |
Preclinical analysis of the antitumor efficacy of TS-1 using human uterine cervical cancer tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Mice; Oxonic Acid; Tega | 2008 |
UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
Topics: 4-Butyrolactone; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocol | 2008 |
[Remarkably reduced tumor marker SCC levels by combined chemotherapy of paclitaxel and S-1 in two cases of advanced cervical cancer].
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2008 |
[Preoperative treatment of FT-207 suppository in cervical cancer-- serum and tumor tissue content of FT-207].
Topics: Cervix Uteri; Female; Fluorouracil; Humans; Suppositories; Tegafur; Uterine Cervical Neoplasms | 1984 |
[Clinical studies of kallidinogenase in combined chemotherapy for cervical cancer].
Topics: Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Kallikreins; Tegafur; Uteri | 1983 |
[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (I) Pharmacokinetics in single administration at a dose of 1 gram].
Topics: Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Kinetics; Rectum; Suppositories; Tegafur; Ut | 1984 |
[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram].
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Humans; Kinetics; Lymp | 1984 |
[Pharmacokinetics of vaginal suppository FT-207 in uterine cervical cancer and radiation therapy].
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Kinetics; Middle Aged; Suppositories; Tegaf | 1984 |
[Comparative pharmacokinetic study between UFT and FT-207 suppo and phase II studies in gynecological malignancies].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female | 1984 |
[A statistical study of management based on prognostic factors after surgical treatment for cervical carcinoma].
Topics: Adenocarcinoma; Administration, Oral; Adult; Age Factors; Carcinoma, Squamous Cell; Combined Modalit | 1984 |
[FT-207 maintenance therapy of malignant gynecologic cancer].
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Middle Aged; Tegafur; Time Factors; Uterine Cer | 1982 |
[Clinical evaluation of Tegafur suppository in the treatment of uterine cancer--with special reference to the drug concentration in the blood, secretion from the pelvic dead space, and tissues of female genital organs].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Genita | 1982 |
[A case report: complete remission of stage IV uterine cervix carcinoma by immuno-chemotherapy with intraarterial infusion using implantable reservoir system].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1995 |
A case of allergic liver injury induced by tegafur.
Topics: Drug Hypersensitivity; Female; Humans; Liver; Liver Function Tests; Lymphocyte Activation; Middle Ag | 1994 |
[A case of uterine cervical cancer in which UFT was an effective preoperative treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 1999 |
[A patient with recurrent uterine cervical cancer successfully treated by combined modality therapy including local injection of anticancer agents based on CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubic | 2000 |
[Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; | 1991 |
Thymidylate synthase inhibition as a predictor of tumor sensitivity of fluorinated pyrimidines.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Mice; Middle A | 1990 |
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin | 1989 |
[Experimental study on the effect of UFT with concomitant radiotherapy of uterine cervical cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carcinoma, Squamous Cell | 1989 |
[The concentration of 5-fluorouracil in blood and tissues of the patients with carcinoma of the cervix after administration of UFT and 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
[Differing progress patterns in cancer of the uterine cervix and variant effects of adjuvant chemotherapy based on histological type].
Topics: Adenocarcinoma; Azirines; Carbazilquinone; Carcinoma; Carcinoma, Squamous Cell; Female; Humans; Lymp | 1986 |
[5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1986 |
[In vitro effects of 5-FU on gynecologic malignant tumor cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line; Cells, Cultured; Colony-Fo | 1986 |
[Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment].
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Eval | 1986 |
Prognostic factors in postoperative management of cervical cancer; a statistical study.
Topics: Adult; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Ris | 1986 |
Individualization of patients for adjuvant chemotherapy after surgical treatment of cervical cancer.
Topics: Adult; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neop | 1987 |
Is postoperative radiotherapy or maintenance chemotherapy necessary for carcinoma of the uterine cervix?
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Middle Ag | 1988 |
[UFT concentration in serum and tissues of patients with gynecologic malignant tumors following oral administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Endometrium; Female; Genital Neoplasms, Female; Huma | 1985 |
[A study on plasma and tissue 5-FU concentrations in patients with cervical cancer treated with UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Tegafur; Uracil; Uteri | 1985 |
[Level of 5-FU in uterine cervical cancer tissue after oral administration of UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cervix Ute | 1985 |